（来源：千龙网） 清晨，孩子们稚嫩的声音就在诊室里响起，与医生温柔的叮嘱交织成一首悦耳的变奏曲。基层医疗，这 道守护儿童健康的防线，正在用专业与温情，呼应万千家庭的牵挂。 在四川省成都市双流区的社区诊室与河南省洛阳市洛宁县的乡镇卫生院，两地医护工作者锚定儿童就医 痛点，因地制宜破解"看病远、看病难、信不过"的困境，让优质儿科服务扎根基层，让每一个儿童都能 被悉心守护。 强基固本：终结奔波之苦 创新破局：就医少跑腿、更贴心 "不用再跑好几个窗口，接种、体检、看病一站式搞定，太省心了！"在西航港社服中心，刚带孩子做完 体检的家长对社区医院赞不绝口。为破解服务碎片化的难题，这里打破科室壁垒，将儿童接种、保健、 门诊、住院等服务串联整合，把辖区划分为11个片区，每个片区都有专属的儿童健康管理团队。家医团 队与网格员双向联动，上门随访、健康宣讲、预约就诊，把服务送到家门口，再也不用等家长"找上 门"。针对不同家庭的需求，这里推出A、B、C、D四类家庭医生服务包，仅2025年，儿童个性化有偿 签约就达1.23万人，定制化服务精准匹配每一份健康需求。 在长水镇，"一站式"服务同样暖了民心。卫生院将儿科诊疗与儿童体检、预防接 ...

| | Programming Language | Ratings | Change | | --- | --- | --- | --- | | t | Python | 21.81% | -2.08% | | C | C | 11.05% | +1.22% | | C | C++ | 8.55% | -2.82% | | র্ড, | Java | 8.12% | -2.54% | | C. | C# | 6.83% | +2.71% | | ાડ | JavaScript | 2.92% | -0.85% | 但Python 的增长似乎触到了天花板，从绝对数值来看，Python 的受欢迎程度在 2025 年 7 月 达到了顶峰，市场份额高达 26.98% 。 本月其份额已回落至 21.81%。 这种变化传递出一个明确信号：一些更专业的语言正在从细分领域逐步蚕食 Python 的优势地盘。 TIOBE 2026 年 02 月份的编程语言排行榜已经公布，官方的标题是： 领域专用语言正向 Python 发起挑战 （ Domain-Specific Languages Challenge Python's Le ...

客户服务电话：95390 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 根据英大基金管理有限公司（以下简称"本公司"）与国新证券股份有限公司（以下简称"国新证券"）签 署的基金销售代理协议及工作安排，自2026年2月9日起，本公司旗下部分基金增加国新证券为销售机 构。 投资者可在国新证券办理本公司旗下部分开放式基金的开户、申购、赎回、定期定额申购等业务，同时 参与国新证券开展的基金申购费率优惠活动（如有）。具体情况公告如下： 一、销售机构主要信息 公司名称：国新证券股份有限公司 1.投资者通过国新证券办理基金定期定额投资业务，应遵循国新证券的具体规定。 2.投资者应当充分了解基金定期定额投资和零存整取等储蓄方式的区别。定期定额投资是引导投资者进 行长期投资、平均投资成本的一种简单易行的投资方式。但是，定期定额投资并不能规避基金投资所固 有的风险，不能保证投资者获得收益，也不是替代储蓄的等效理财方式。 公司网站：www.crsec.com.cn 二、新增代理销售基金名称和代码 ■ 注：英大安鑫66个月定期开放债券、英大通佑一年定开债券处于封闭期，暂不办理申购（含转换转入） 等业务；英 ...

Core Viewpoint - Huatai Asset Management has undergone a significant management reshuffle, promoting internal candidates to key positions, signaling a focus on stability and continuity in leadership as the company aims to recover from previous performance declines [1][2][18]. Management Changes - Jiang Xiaoyang has been promoted to Chairman, while Zhu Qian becomes the new General Manager, and Liu Bowen takes on the role of Chief Risk Officer in addition to his other responsibilities [1][2][18]. - All three newly appointed executives have extensive experience within the Huatai system, indicating a preference for internal talent development [5][24]. Financial Performance - In the first half of 2025, Huatai Asset Management reported a revenue of 1.21 billion yuan, a year-on-year increase of 37.73%, and a net profit of 713 million yuan, up 47.22% [18][25]. - The total asset management scale reached 6270.32 billion yuan, reflecting a year-on-year growth of 23.92% [11][28]. Market Position - As of the end of 2025, Huatai's public fund asset management scale was 180.83 billion yuan, ranking second among brokerage asset management companies [13][30]. - The company has issued a total of 994 ABS products, with a cumulative issuance scale of 1011.12 billion yuan, placing it third in the industry [26][30]. Product Offerings - Huatai Asset Management's product range includes private equity, special asset management products, and public funds, with a significant portion of its management scale derived from public funds and collective asset management [11][28]. - The company has a high concentration in money market funds, which accounted for 85.59% of its total fund scale as of the end of 2025 [30][32]. Competitive Landscape - The asset management sector is facing intense competition from bank wealth management and public funds, but Huatai maintains a unique advantage in fixed income products amid a volatile bond market [15][32]. - The new leadership is expected to focus on consolidating strengths in fixed income while exploring opportunities in equity investments [34].

Group 1 - The fund distribution industry is experiencing a transformation with new entrants adopting a "buy-side advisory" approach, which is reshaping the market dynamics [1][2] - New institutions like E Fund Wealth Management are being added as distribution partners for multiple funds, indicating a shift in strategy among fund companies [2] - The entry of new players is seen as a potential catalyst for accelerating industry evolution, despite the prevailing challenges faced by traditional players [2][3] Group 2 - The industry is witnessing a rapid reshuffle, with many traditional firms exiting the market due to increasing competition and regulatory pressures [3] - The recent fee reforms initiated in July 2023 are driving a systematic adjustment in the fund distribution sector, emphasizing the need for a more sophisticated approach beyond the traditional sales model [3][4] - The transition towards a buy-side advisory model is being supported by policy changes and market demands, which are expected to enhance the growth potential of the public fund industry [4]

Core Viewpoint - Chengdu Olin Biotechnology Co., Ltd. is facing a contract dispute involving two core vaccine products, leading to the freezing of some bank accounts, which has raised market concerns. The plaintiff claims a total of 19.2 million yuan in technical commissions and penalties, exceeding the company's net profit for the first half of 2025, highlighting potential risks in intellectual property compliance and information disclosure [1][4]. Group 1: Historical Cooperation and Disclosure Issues - The plaintiff asserts that a contract was signed in 2011, providing technical materials for specific vaccines, but no mention of this relationship was found in the company's IPO documentation from 2021, raising questions about the completeness of the IPO materials [5][6]. - The company emphasized its focus on independent research and collaboration with academic institutions in its prospectus, omitting the key technical provider, which could lead to regulatory scrutiny regarding compliance and potential omissions during the IPO process [5][6]. Group 2: Financial Impact of the Lawsuit - The frozen amount of 19.2 million yuan exceeds the company's net profit of 13.2 million yuan for the first half of 2025. Although the company claims the frozen accounts are not essential for operations, the liquidity pressure and financial risks cannot be overlooked [2][3]. - The two products involved in the lawsuit are projected to generate nearly 50 million yuan in revenue in 2024, with gross margins exceeding 76%, making them significant profit sources for the company. Any impact on production and sales due to the lawsuit could directly affect the company's performance [6][7]. Group 3: Legitimacy of Technology Sources - The company asserts that the products in question are legally marketed and compliant with regulations, claiming no rights defects. However, the plaintiff's claims challenge the legitimacy of the technology sources, which could jeopardize the company's rights and affect product qualifications and commercial sustainability if the court supports the plaintiff [7][8]. - The dispute reveals potential weaknesses in the company's early technology cooperation management, contract execution, and intellectual property compliance, which are critical for a technology-driven enterprise [7][8]. Group 4: Compliance and Transparency - The lawsuit, stemming from a contract signed 14 years ago, underscores the need for improved consistency in information disclosure and management of technology cooperation, as well as heightened awareness of legal risk prevention [3][8]. - In the context of stringent regulations and high compliance requirements in the pharmaceutical industry, companies must focus not only on product development and market expansion but also on strengthening internal controls and compliance measures to maintain transparency and stability in the eyes of investors and the market [3][8].

Core Insights - C has regained the title of "Programming Language of the Year" in the 2025 TIOBE index, marking a significant rise in its ranking after three years [1] - The programming landscape is shifting, with C and C++ swapping positions, and C language maintaining its dominance in the embedded systems market [1] - Perl has made a remarkable leap from 32nd to 11th place, while R language has returned to the top ten, driven by growth in the data science sector [1] - Go language has fallen out of the top ten, and Ruby has dropped out of the top twenty, indicating a potential decline in their usage [1] Ranking Summary - Python remains the top programming language with a rating of 22.61%, although it has seen a slight decrease of 0.68% [2] - C has moved up to the second position with a rating of 10.99%, showing an increase of 2.13% [2] - Java and C++ have dropped to third and fourth positions, respectively, with Java at 8.71% (down 1.44%) and C++ at 8.67% (down 1.62%) [2] - C holds the fifth position with a rating of 7.39%, reflecting an increase of 2.94% [2] - Visual Basic and SQL are in sixth and eighth positions, respectively, with ratings of 2.41% and 2.27% [2] - R has climbed to the tenth position with a rating of 1.82%, up by 0.81% [2] - Perl's rise to 11th place with a rating of 1.63% marks a significant increase of 1.14% [2] - Rust has moved to 13th place with a rating of 1.51%, showing a modest increase of 0.34% [2] - Go has dropped to 16th place with a rating of 1.24%, down by 1.37% [2]

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. (Olin Bio, 688319.SH) is facing a lawsuit regarding two core vaccine products, leading to the freezing of some bank accounts by the court [1][2]. Group 1: Lawsuit Details - The plaintiff, Wang Jianhua, is requesting Olin Bio to pay a total of 16 million yuan for commissions related to two vaccine products and an additional 3.2 million yuan in penalties [1]. - Olin Bio has stated that it believes the lawsuit lacks sufficient factual and legal basis and will actively defend itself [2]. - The lawsuit traces back to a technical cooperation agreement signed in 2011, but Olin Bio's IPO prospectus did not mention Wang Jianhua's involvement or the claim for commissions [2][3]. Group 2: Financial Impact - Olin Bio's bank accounts have been partially frozen, with one account holding 19.2 million yuan, which represents 2.06% of the company's latest audited net assets and 8.57% of its cash balance [2]. - The lawsuit's claimed amount exceeds Olin Bio's net profit for the first half of 2025 [5]. - In 2024, Olin Bio reported revenues of 58.89 million yuan, a year-on-year increase of 18.69%, and a net profit of 2.08 million yuan, also up by 18.24% [4].

Core Insights - 80% of AI startups in the US are now opting for Chinese general models instead of OpenAI's models, indicating a significant shift in preference due to the practicality and effectiveness of Chinese models [1][11][13] Group 1: Performance of Chinese AI Models - Chinese models, particularly in image generation, have established themselves at the forefront globally, with Alibaba's Image series and Tencent's Hunyuan Image models achieving top rankings [5][7] - In the image editing sector, Chinese companies hold 6 out of the top 16 positions, representing approximately one-third of the global market share [5] - ByteDance's models have notably secured the second, third, and fifth positions globally, showcasing China's strong presence in the top tier of AI models [7] - In the video model category, Chinese firms dominate with 7 out of the top 16 models, indicating a robust ecosystem outside of the US [9] Group 2: Comparison with US AI Development - The US is focusing on three core areas: advancing AI chip technology, building large-scale AI infrastructure, and developing closed-source models, aiming for high-tech breakthroughs [15][17] - In contrast, China is pursuing a more application-oriented approach, leveraging its status as the largest manufacturing and hardware nation to integrate AI across the entire industrial chain [21][23] - China's open-source model strategy encourages broader participation from enterprises and developers, facilitating rapid technological iteration and application across various industries [25] Group 3: Market Dynamics and Future Implications - The shift in preference among US startups reflects a broader trend where Chinese models are seen as more practical and adaptable to specific business needs [13][15] - The differing paths of AI development in China and the US are not a zero-sum game; rather, they may drive innovation and transformation in the global AI landscape [25][27]

Core Viewpoint - Oulin Bio has received a lawsuit notification from the Chengdu Intermediate People's Court regarding a claim made by the plaintiff Wang Jianhua for commission payments related to specific vaccine products [1] Group 1: Lawsuit Details - The plaintiff, Wang Jianhua, claims to have provided technical materials for two vaccine products and is seeking a total of 16 million yuan in commission payments [1] - Additionally, Wang Jianhua is requesting a penalty of 3.2 million yuan, calculated at 20% of the claimed commission amount [1] - Oulin Bio has acknowledged the lawsuit and asserts that the claims lack sufficient factual and legal basis, indicating a strong stance against the allegations [1] Group 2: Current Status - As of the date of the announcement, the lawsuit has not yet gone to trial, and the claimed amounts represent the plaintiff's assertions rather than any court ruling [1]